- Home
- PNI vs SERA Comparison
PNI vs SERA Comparison
Compare PNI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | SERA |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 75.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PNI | SERA |
|---|---|---|
| Price | $6.79 | $2.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 77.9K | 34.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $6.48 | $1.56 |
| 52 Week High | $7.20 | $3.95 |
Technical Indicators
Market Signals| Indicator | PNI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 24.97 | 52.57 |
| Support Level | $6.64 | $1.68 |
| Resistance Level | $7.07 | $2.40 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.67 | 47.24 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.